Granted Patent B2

US 10,501,807 · App. 15/919,394 · Granted Dec 10, 2019

Inventors: Steven Stone (Salt Lake City, UT); Alexander Gutin (Salt Lake City, UT); Susanne Wagner (Salt Lake City, UT); Julia Reid (Salt Lake City, UT)

Assignee: MYRIAD GENETICS, INC.

C12Q1/6886G16B20/00C12Q2600/106C12Q2600/118C12Q2600/158G16B40/00

Abstract

Claims (17)

1. A method for treating prostate cancer in a patient, the method comprising:

(1) obtaining a sample comprising prostate cancer tumor tissue from said patient;

(2) determining the expression of a panel of genes comprising NUSAP1 and UBE2C in said sample comprising prostate cancer tumor tissue;

(3) prognosing said patient as having a decreased likelihood of prostate cancer progression when the expression of the genes NUSAP1 and UBE2C in said sample is lower than the expected expression of the genes NUSAP1 and UBE2C in prostate cancer tumor tissue from a reference population;

(4) administering to said patient active surveillance based on the prognosis for a period of time until symptoms develop or there are signs that the cancer growth is accelerating; and

(5) administering active treatment based on the developed symptoms or accelerated growth, wherein the active treatment is one or more of hormonal therapy, chemotherapy, radiation therapy and surgery.

2. The method of claim 1 , wherein said prognosing step further comprises incorporating into a statistical model the expression of the genes NUSAP1 and UBE2C in said sample.

3. The method of claim 1 , wherein said reference population comprises patients with similar clinical parameters.

4. The method of claim 3 , wherein said clinical parameters are Gleason score and tumor stage.

5. A method for treating prostate cancer in a patient, the method comprising:

(1) obtaining a sample comprising prostate cancer tumor tissue from said patient;

(2) determining the expression of a panel of genes comprising NUSAPI and UBE2C in said sample comprising prostate cancer tumor tissue;

(3) prognosing said patient as having an increased likelihood of prostate cancer progression when the expression of the genes NUSAPI and UBE2C in said sample is higher than the expected expression of the genes NUSAPI and UBE2C in prostate cancer tumor tissue from a reference population; and

(4) administering to said patient one or more of hormonal therapy, chemotherapy, radiation therapy and surgery based on the prognosis.

6. The method of claim 5 , wherein said prognosing step further comprises incorporating into a statistical model the expression of the genes NUSAPI and UBE2C in said sample.

7. The method of claim 5 , wherein said reference population comprises patients with similar clinical parameters.

8. The method of claim 7 , wherein said clinical parameters are Gleason score and tumor stage.

Assignments (5)

Continuity (10)